

Inveready closes its new Biotech fund surpassing the 50 million euros target

San Sebastián, July 7, 2023.

Inveready has closed the fourth generation of its biotech funds, Inveready Biotech IV. In total, it will be a closure of 52.85 million euros this July with 60% of private investment. The Biotech team continues with the support of Roger Piqué, Sara Secall, and Josep Maria Echarri as key partners in this investment strategy and is strengthened with the promotion of María Poveda and Antonio Herce as Investment Directors, with the addition of an additional professional in the short term.